An internal standard for the quantification of fosinopril
Related Products
Unlabeled Version(s)
21899Fosinopril (sodium salt)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Fosinopril-d7 (sodium salt)

Item No. 31917

Technical Information
Formal Name
(2S,4S)-4-cyclohexyl-1-(2-((R)-((S)-2-methyl-1-(propionyloxy)propoxy)(4-(phenyl-d5)butyl-4,4-d2)phosphoryl)acetyl)pyrrolidine-2-carboxylate, monosodium salt
CAS Number
1217819-83-4
Molecular Formula
C30H38D7NO7P • Na
Formula Weight
Purity
≥99% deuterated forms (d1-d7)
Formulation
A solid
Acetonitrile:Methanol (1:1): SolubleDMSO: SolubleWater: Soluble
SMILES
[O-]C([C@@H]1C[C@@](CN1C(C[P@](O[C@@H](C(C)C)OC(CC)=O)(CCCC([2H])([2H])C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])=O)=O)([H])C3CCCCC3)=O.[Na+]
InChi Code
InChI=1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39-;/m1./s1/i5D,7D,8D,13D,14D,15D2;
InChi Key
TVTJZMHAIQQZTL-ZPRIPZGZSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Product Description

    Fosinopril-d7 is intended for use as an internal standard for the quantification of fosinopril (Item No. 21899) by GC- or LC-MS. Fosinopril is a prodrug form of the angiotensin-converting enzyme (ACE) inhibitor fosinoprilat.1 Oral administration of fosinopril inhibits angiotensin I-induced pressor responses in normotensive rats, dogs, and monkeys when administered at doses of 15, 15, and 10 µmol/kg, respectively. Fosinopril (2.5 mg/kg) reduces fractional shortening and decreases left ventricular size in a porcine model of congestive heart failure.2 Formulations containing fosinopril have been used in the treatment of hypertension and congestive heart failure.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. DeForrest, J.M., Waldron, T.L., Harvey, C., et alFosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: In vitro and preclinical in vivo pharmacology. J. Cardiovasc. Pharmacol. 14(5), 730-736 (1989).

    2. McElmurray, J.H., III, Mukherjee, R., New, R.B., et alAngiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry. J. Pharmacol. Exp. Ther. 291(2), 799-811 (1999).